Linda de Jonge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Linda de Jonge has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Marian K. Bakker
Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4 shared publicationsH. Jens Bos
Unit of Pharmaco Epidemiology and Pharmaco Economics, Department of Pharmacy University of Groningen Groningen The Netherlands
2 shared publicationsIrene M. van Langen
University of Groningen, University Medical Center Groningen, Department of Genetics
2 shared publicationsLolkje T. W. de Jong-Van Den Berg
University of Groningen, Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics
2 shared publicationsAmanda J. Neville
Registro IMER-IMER Registry (Emila Romagna Registry of Birth Defects), Center for Clinical and Epidemiological Research, University of Ferrara, Ferrara, Italy
1 shared publication- Anna Pierini
Unit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy
1 shared publication
Latest Publications
- Open Access
- 8 July 2015
- Published by Springer Nature in Drug Safety
- Vol. 38 (11) , 1083-1093
Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study
Research on associations between medication use during pregnancy and congenital anomalies is significative for assessing the safe use of a medicine in pregnancy. Congenital anomaly (CA) registries do not have optimal information on medicine exposure, in contrast to prescription databases. Linkage of prescription databases to the CA registries is a potentially effective method of obtaining accurate information on medicine use in pregnancies and the risk of congenital anomalies.
- 8 July 2015
- Published by Springer Nature in Drug Safety
- Vol. 38 (11) , 1083-1093
Open AccessImproving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study
Research on associations between medication use during pregnancy and congenital anomalies is significative for assessing the safe use of a medicine in pregnancy. Congenital anomaly (CA) registries do not have optimal information on medicine exposure, in contrast to prescription databases. Linkage of prescription databases to the CA registries is a potentially effective method of obtaining accurate information on medicine use in pregnancies and the risk of congenital anomalies.
- Open Access
- 4 June 2015
- Published by Springer Nature in Drug Safety
- Vol. 38 (8) , 737-747
Actual Use of Medications Prescribed During Pregnancy: A Cross-Sectional Study Using Data from a Population-Based Congenital Anomaly Registry
Data from prescription databases are increasingly being used to study associations between maternal medications used in pregnancy and congenital anomalies. We therefore investigated the extent to which prescriptions reflect the actual use of medication during pregnancy, and whether medicines used during pregnancy are taken according to the prescribed dosage and duration.
- 4 June 2015
- Published by Springer Nature in Drug Safety
- Vol. 38 (8) , 737-747
Open AccessActual Use of Medications Prescribed During Pregnancy: A Cross-Sectional Study Using Data from a Population-Based Congenital Anomaly Registry
Data from prescription databases are increasingly being used to study associations between maternal medications used in pregnancy and congenital anomalies. We therefore investigated the extent to which prescriptions reflect the actual use of medication during pregnancy, and whether medicines used during pregnancy are taken according to the prescribed dosage and duration.
- 3 August 2013
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 23 (1) , 60-68
Antibiotics prescribed before, during and after pregnancy in the Netherlands: a drug utilization study
Purpose: To describe the prescription of antibiotics before, during and after pregnancy, and the trends over a 16‐year period in the Netherlands, and to determine whether they were prescribed according to national guidelines.Methods: The IADB (http://iadb.nl) contains prescriptions dispensed by community pharmacies in the Netherlands. We extracted information on 18 873 pregnancies for 14 969 women between 1994 and 2009, focusing on antibiotics dispensed in the four trimesters before conception to two trimesters after birth (nine trimesters in total). We calculated trends in prescription rates during pregnancy and over time, and also compared the prescription of antibiotics in the Netherlands with safety category based on the Australian Drug Evaluation Committee.Results: During pregnancy 20.8% of the women were prescribed at least one antibiotic. The ‘beta‐lactam antibacterials/penicillins’ group and the specific antibiotic amoxicillin were most commonly prescribed in the nine trimesters covered. The prescription rate of the ‘other antibacterials’ group during pregnancy increased over the years, in contrast to that of the ‘sulphonamides/trimethoprim’ group, which decreased. In total, 2.0% of pregnancies were exposed to a ‘potentially harmful’ antibiotic and 0.8% to a ‘harmful’ antibiotic. Compared with the period before conception, ‘safe’ antibiotics were prescribed more often during pregnancy than the other groups.Conclusions: One in five women was prescribed at least one antibiotic during pregnancy in the Netherlands, which is comparable with rates in other European countries. Our results suggest that antibiotics appear to be prescribed to pregnant women generally in accordance with national recommendations. Copyright © 2013 John Wiley & Sons, Ltd.
- 3 August 2013
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 23 (1) , 60-68
Antibiotics prescribed before, during and after pregnancy in the Netherlands: a drug utilization study
Purpose: To describe the prescription of antibiotics before, during and after pregnancy, and the trends over a 16‐year period in the Netherlands, and to determine whether they were prescribed according to national guidelines.Methods: The IADB (http://iadb.nl) contains prescriptions dispensed by community pharmacies in the Netherlands. We extracted information on 18 873 pregnancies for 14 969 women between 1994 and 2009, focusing on antibiotics dispensed in the four trimesters before conception to two trimesters after birth (nine trimesters in total). We calculated trends in prescription rates during pregnancy and over time, and also compared the prescription of antibiotics in the Netherlands with safety category based on the Australian Drug Evaluation Committee.Results: During pregnancy 20.8% of the women were prescribed at least one antibiotic. The ‘beta‐lactam antibacterials/penicillins’ group and the specific antibiotic amoxicillin were most commonly prescribed in the nine trimesters covered. The prescription rate of the ‘other antibacterials’ group during pregnancy increased over the years, in contrast to that of the ‘sulphonamides/trimethoprim’ group, which decreased. In total, 2.0% of pregnancies were exposed to a ‘potentially harmful’ antibiotic and 0.8% to a ‘harmful’ antibiotic. Compared with the period before conception, ‘safe’ antibiotics were prescribed more often during pregnancy than the other groups.Conclusions: One in five women was prescribed at least one antibiotic during pregnancy in the Netherlands, which is comparable with rates in other European countries. Our results suggest that antibiotics appear to be prescribed to pregnant women generally in accordance with national recommendations. Copyright © 2013 John Wiley & Sons, Ltd.
- 5 July 2013
- Published by Springer Nature in Drug Safety
- Vol. 36 (11) , 1069-1078
Identifying Associations between Maternal Medication Use and Birth Defects Using a Case-Population Approach: An Exploratory Study on Signal Detection
Background The effects of many drugs on the unborn child are unknown. In a case-population design, drug exposure of cases is compared with that of a source population; this kind of study can be useful for generating signals. Objective To see whether a comparison of drug use rates from the birth defect registry EUROCAT NNL (cases) with prescription rates from a population-based prescription database, the IADB (population), could be used to detect signals of teratogenic risk of drugs. Methods We defined 3,212 cases from the EUROCAT NNL database, a population-based birth defect registry in the Northern Netherlands and 29,223 population controls from the IADB, a prescription database with data from community pharmacies in the same geographical area, born between 1998 and 2008. We classified the malformations of the 3,212 cases into several malformation groups according to organ system (based on the International Classification of Diseases codes and the EUROCAT guidelines). If a child had multiple malformations in several organ systems (n = 253, 7.9 %), he/she was counted in all the categories represented. For several groups of malformations we calculated rate ratios (RR) and 95 % confidence intervals for drugs acting on the central nervous system and for drugs considered to be safe for use in pregnancy. The RRs were based on first-trimester drug use rates from the cases in the EUROCAT NNL database and prescription rates from the population controls in the IADB. Results For drugs acting on the central nervous system we found significantly increased RRs for the anti-epileptic drug valproic acid and for some selective serotonin reuptake inhibitors. For drugs considered to be safe only the anti-hypertensive methyldopa showed significantly increased RRs. Conclusion We show that a case-population study is a suitable method for detecting signals of possible teratogenicity, provided that the teratogenic effects and the drugs under study are as specific as possible and the drugs are widely used.
- 5 July 2013
- Published by Springer Nature in Drug Safety
- Vol. 36 (11) , 1069-1078
Identifying Associations between Maternal Medication Use and Birth Defects Using a Case-Population Approach: An Exploratory Study on Signal Detection
Background The effects of many drugs on the unborn child are unknown. In a case-population design, drug exposure of cases is compared with that of a source population; this kind of study can be useful for generating signals. Objective To see whether a comparison of drug use rates from the birth defect registry EUROCAT NNL (cases) with prescription rates from a population-based prescription database, the IADB (population), could be used to detect signals of teratogenic risk of drugs. Methods We defined 3,212 cases from the EUROCAT NNL database, a population-based birth defect registry in the Northern Netherlands and 29,223 population controls from the IADB, a prescription database with data from community pharmacies in the same geographical area, born between 1998 and 2008. We classified the malformations of the 3,212 cases into several malformation groups according to organ system (based on the International Classification of Diseases codes and the EUROCAT guidelines). If a child had multiple malformations in several organ systems (n = 253, 7.9 %), he/she was counted in all the categories represented. For several groups of malformations we calculated rate ratios (RR) and 95 % confidence intervals for drugs acting on the central nervous system and for drugs considered to be safe for use in pregnancy. The RRs were based on first-trimester drug use rates from the cases in the EUROCAT NNL database and prescription rates from the population controls in the IADB. Results For drugs acting on the central nervous system we found significantly increased RRs for the anti-epileptic drug valproic acid and for some selective serotonin reuptake inhibitors. For drugs considered to be safe only the anti-hypertensive methyldopa showed significantly increased RRs. Conclusion We show that a case-population study is a suitable method for detecting signals of possible teratogenicity, provided that the teratogenic effects and the drugs under study are as specific as possible and the drugs are widely used.